ArticleJournal of agricultural and food chemistry2026
Gastroprotective [6]-Gingerol Aspirinate as a Novel Aspirin-Derived Chemopreventive Agent Attenuating Colitis.
Article in Journal of agricultural and food chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Daily low-dose aspirin reduces cardiovascular disease and colorectal cancer risk, but it is limited by gastrointestinal toxicity. To enhance safety and efficacy, we developed [6]-gingerol aspirinate (GAS) by conjugating aspirin with ginger-derived bioactive [6]-gingerol. This study evaluated GAS in a dextran sodium sulfate (DSS)-induced colitis mouse model. GAS significantly improved clinical symptoms and reduced pro-inflammatory markers (IL-6, TNF-α, IL-1β, TGF-β, and COX-2), whereas aspirin alone showed minimal protection. Untargeted LC/MS-based metabolomics revealed that GAS reversed 73 DSS-altered metabolites, including those related to lipids, amino acids, and carbohydrate metabolisms, many previously linked to inflammatory bowel disease and colorectal cancer. Correlation analysis showed strong associations between these metabolites and inflammatory cytokines, suggesting their involvement in GAS-mediated anti-inflammatory effects. Overall, GAS provides superior protection against colitis through coordinated suppression of inflammation and modulation of disease-associated metabolic pathways, highlighting its potential as a safer chemopreventive agent and identification of candidate metabolic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.